Monte Rosa Therapeutics Inc
GLUEHealthcare|Biotechnology|USA
$23.02
-1.48 (-6.04%)
Tangible Book
$6.19
Financials
Financial Snapshot
Market Cap
$1.94B
Enterprise Value
$627.2M
Revenue (TTM)
$43.0M
Net Income (TTM)
$-130.0M
Cash & Equivalents
—
Net Cash/Share
$5.36
Free Cash Flow (TTM)
$-19.7M
Operating CF (TTM)
$-14.7M
Debt/Equity
0.08
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$3.7M
Monthly Burn
$1.2M
Est. Runway
—
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.0M | $41.7M | $346.1M | $262.8M | $232.4M | $372.1M | $377.1M | $666.2M | |
| Operating Cash Flow | $-6.2M | $-23.1M | $-59.4M | $-92.5M | $-43.8M | $42.0M | $-22.8M | $-14.7M | |
| Free Cash Flow | $-7.6M | $-26.4M | $-69.1M | $-105.4M | $-62.8M | $38.0M | $-27.5M | $-19.7M | |
| Capital Expenditure | $-1.4M | $-3.4M | $-9.7M | $-12.9M | $-19.0M | $-4.0M | $-4.7M | $-5.0M | |
| Financing Cash Flow | $15.0M | $60.1M | $377.6M | $20.5M | $27.5M | $98.9M | $30.4M | $358.7M |
R&D Spending
R&D (TTM)
$153.4M
R&D Intensity
357.1%
R&D Growth YoY
+8.4%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $75.6M | $123.7M | $43.0M | |
| R&D Expense | $7.3M | $24.0M | $57.2M | $85.1M | $111.3M | $121.6M | $141.5M | $153.4M | |
| R&D % of Revenue | — | — | — | — | — | 160.8% | 114.4% | 357.1% | |
| SG&A | $644.0K | $4.0M | $15.7M | $27.3M | $32.0M | $35.2M | $36.4M | $37.9M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $75.6M | $123.7M | $43.0M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $75.6M | $123.7M | $43.0M | |
| R&D | $7.3M | $24.0M | $57.2M | $85.1M | $111.3M | $121.6M | $141.5M | $153.4M | |
| SG&A | $644.0K | $4.0M | $15.7M | $27.3M | $32.0M | $35.2M | $36.4M | $37.9M | |
| Operating Income | $-8.0M | $-28.0M | $-72.9M | $-112.4M | $-143.3M | $-81.1M | $-54.2M | $-148.3M | |
| Interest Expense | $-1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-7.7M | $-35.9M | $-74.0M | $-108.5M | $-135.0M | $-70.1M | $-39.7M | $-131.9M | |
| Net Income | $-7.7M | $-35.9M | $-74.0M | $-108.5M | $-135.4M | $-72.7M | $-38.6M | $-130.0M | |
| EPS (Diluted) | -0.69 | -1.65 | -2.96 | -2.30 | -2.63 | -0.98 | -0.46 | -1.63 | |
| EBITDA | $-7.7M | $-27.5M | $-70.8M | $-108.6M | $-137.1M | $-73.0M | $-45.9M | $-139.9M | |
| Shares Out. (M) | 11.14 | 21.74 | 25.00 | 47.23 | 51.40 | 73.91 | 83.07 | 99.88 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.0M | $41.7M | $346.1M | $54.9M | $128.1M | $224.3M | $129.9M | $159.9M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $207.9M | $104.3M | $147.9M | $247.2M | $506.4M | |
| Total Current Assets | $9.8M | $43.6M | $348.7M | $275.9M | $236.2M | $377.4M | $393.2M | $677.5M | |
| Total Assets | $11.1M | $49.4M | $366.3M | $342.4M | $303.8M | $438.7M | $448.7M | $736.4M | |
| Total Current Liabilities | $4.3M | $29.3M | $16.6M | $25.6M | $46.6M | $156.9M | $64.2M | $71.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $23.2M | $98.1M | $18.8M | $71.0M | $124.5M | $215.8M | $215.6M | $214.5M | |
| Stockholders' Equity | $-12.1M | $-48.7M | $347.5M | $271.4M | $179.3M | $222.9M | $233.1M | $521.9M | |
| Retained Earnings | $-12.2M | $-48.1M | $-122.0M | $-230.5M | $-365.9M | $-438.6M | $-477.2M | $-521.7M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-6.2M | $-23.1M | $-59.4M | $-92.5M | $-43.8M | $42.0M | $-22.8M | $-14.7M | |
| Capital Expenditure | $-1.4M | $-3.4M | $-9.7M | $-12.9M | $-19.0M | $-4.0M | $-4.7M | $-5.0M | |
| Free Cash Flow | $-7.6M | $-26.4M | $-69.1M | $-105.4M | $-62.8M | $38.0M | $-27.5M | $-19.7M | |
| Investing Cash Flow | $-1.4M | $-3.4M | $-9.7M | $-219.2M | $88.8M | $-44.5M | $-101.8M | $-262.6M | |
| Financing Cash Flow | $15.0M | $60.1M | $377.6M | $20.5M | $27.5M | $98.9M | $30.4M | $358.7M | |
| Issuance of Stock | $0.00 | $0.00 | $237.8M | $20.1M | $0.00 | $944.0K | $24.3M | $348.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $-116.0K | $-641.0K | $-357.0K | $-357.0K | |
| Issuance of Debt | $750.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $354.0K | $5.2M | $11.7M | $16.7M | $18.1M | $18.9M | $19.5M | |
| Net Change in Cash | $7.4M | $33.6M | $308.5M | $-291.2M | $72.5M | $96.4M | $-94.3M | $81.4M |
Dilution Tracker
Shares outstanding grew 299.5% over 5 years — significant dilution
Shares Outstanding
100M
5-Year Share Growth
+299.5%
Stock Issuance (TTM)
$348.6M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 11.14 | 21.74 | 25.00 | 47.23 | 51.40 | 73.91 | 83.07 | 99.88 | |
| YoY Change % | — | 95.1% | 15.0% | 88.9% | 8.8% | 43.8% | 12.4% | 20.2% | |
| Stock Issuance | $0.00 | $0.00 | $237.8M | $20.1M | $0.00 | $944.0K | $24.3M | $348.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $-116.0K | $-641.0K | $-357.0K | $-357.0K | |
| Stock Based Comp. | $0.00 | $354.0K | $5.2M | $11.7M | $16.7M | $18.1M | $18.9M | $19.5M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -107.3% | -43.8% | -345.2% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -96.1% | -31.2% | -302.7% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -96.5% | -37.1% | -325.8% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 50.3% | -22.2% | -45.8% | |
| ROE % | 0.0% | 0.0% | -49.5% | -35.1% | -60.1% | -36.2% | -16.9% | -42.1% | |
| ROA % | -69.8% | -118.7% | -35.6% | -30.6% | -41.9% | -19.6% | -8.7% | -27.1% | |
| R&D / Revenue | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 46.17 / 74.41
Industry Med.27.51
P/S44.96
Historical2.03 / 12.70 / 400.56
Industry Med.9.49
P/B3.72
Historical0.88 / 1.76 / 6.83
Industry Med.2.93
EV/EBITDA-9.42
Historical-37.93 / -1.49 / 64.34
Industry Med.13.02
EV/Revenue30.67
Historical0.27 / 9.66 / 268.81
Industry Med.8.59
P/FCF—
Historical4.38 / 15.55 / 30.91
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$6.19
Net Current Assets
$5.490
Net-Net Working Capital
$5.36
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | 6.78 | 10.53 | 44.96 | |
| PB Ratio | 0.00 | 0.00 | 2.73 | 1.38 | 1.58 | 1.91 | 4.41 | 3.72 | |
| EV/EBITDA | 0.00 | 0.00 | -8.54 | -1.47 | -0.71 | -1.33 | -15.04 | -9.42 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29 | 5.58 | 30.67 |
Analyst Estimates & Quality
Altman Z-Score
4.90
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
5.83
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $44.48M | $58.17M | $17.80M |
| Net Income | $-152.90M | $-182.28M | $-224.30M |
| EPS | -1.63 | -1.81 | -2.29 |
| Book Value per Share | 2.07 | 1.00 | 0.00 |
| Operating Cash Flow per Share | 0.30 | 0.67 | 0.00 |
| Operating CF | $29.97M | $66.92M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Developing a portfolio of novel and proprietary molecular glue degraders (MGDs) | $123.7M |
By Geography
| Segment | 2025 |
|---|---|
| Switzerland | $111.3M |
| United States | $12.4M |